- Home
- TWST vs KNSA Comparison
TWST vs KNSA Comparison
Compare TWST & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWST | KNSA |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TWST | KNSA |
|---|---|---|
| Price | $58.57 | $53.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $46.88 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.3M | 686.8K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.89 | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | $376,572,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $18.91 | $37.48 |
| Revenue Next Year | $15.07 | $17.87 |
| P/E Ratio | ★ N/A | $200.04 |
| Revenue Growth | 20.32 | ★ 60.09 |
| 52 Week Low | $23.30 | $25.71 |
| 52 Week High | $66.06 | $59.87 |
Technical Indicators
Market Signals| Indicator | TWST | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 52.49 |
| Support Level | $41.85 | $40.67 |
| Resistance Level | $66.06 | $59.87 |
| Average True Range (ATR) | 3.84 | 2.19 |
| MACD | -0.50 | -0.66 |
| Stochastic Oscillator | 84.02 | 21.96 |
Price Performance
Historical ComparisonAbout TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.